ArticleProceedings of the National Academy of Sciences of the United States of America2010
High-throughput engineering and analysis of peptide binding to class II MHC.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 64 citations in OpenAlex.
- Whole-protein screening and multi-modal profiling of antigen-specific CD4Nature communications · 2026Article
- Pan-prediction of major histocompatibility complex class II-restricted epitopes across specieshLife · 2026Article
- A common network of residue-residue contacts underlies interactions between peptides and HLA class II complex.PloS one · 2026Article
- A general system for targeting MHC class II-antigen complex via a single adaptable loop.Nature biotechnology · 2025Article
- SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.Genome medicine · 2025Article
- Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.Nature reviews. Drug discovery · 2024Review
- Feature Selection Enhances Peptide Binding Predictions for TCR-Specific Interactions.bioRxiv : the preprint server for biology · 2024Article
- Structure-aware deep model for MHC-II peptide binding affinity prediction.BMC genomics · 2024Article
- A general platform for targeting MHC-II antigens via a single loop.bioRxiv : the preprint server for biology · 2024Article
- Feature selection enhances peptide binding predictions for TCR-specific interactions.Frontiers in immunology · 2024Article
- MHCII-peptide presentation: an assessment of the state-of-the-art prediction methods.Frontiers in immunology · 2024Review
- High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation.Nature communications · 2023Article
- Proteome-Scale Screening to Identify High-Expression Signal Peptides with Minimal N-Terminus Biases via Yeast Display.ACS synthetic biology · 2022Article
- A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding.eLife · 2022Article
- High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape.Science advances · 2022Article
- Rapid Identification of MHCII-Binding Peptides Through Microsphere-Assisted Peptide Screening (MAPS).Methods in molecular biology (Clifton, N.J.) · 2022Article
- TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review.Frontiers in immunology · 2022Review
- Yeast Surface Display: New Opportunities for a Time-Tested Protein Engineering System.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA).Cellular & molecular immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Class II major histocompatibility complex (MHC-II) proteins govern stimulation of adaptive immunity by presenting antigenic peptides to CD4+ T lymphocytes. Many allelic variants of MHC-II exist with implications in peptide presentation and immunity; thus, high-throughput experimental tools for rapid and quantitative analysis of peptide binding to MHC-II are needed. Here, we present an expression system wherein peptide and MHC-II are codisplayed on the surface of yeast in an intracellular association-dependent manner and assayed by flow cytometry. Accordingly, the relative binding of different peptides and/or MHC-II variants can be assayed by genetically manipulating either partner, enabling the application of directed evolution approaches for high-throughput characterization or engineering. We demonstrate the application of this tool to map the side-chain preference for peptides binding to HLA-DR1 and to evolve novel HLA-DR1 mutants with altered peptide-binding specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.